Cargando…
Tamoxifen Resistance in Breast Cancer
Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer. The most challenging issue...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Applied Pharmacology
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794521/ https://www.ncbi.nlm.nih.gov/pubmed/24130921 http://dx.doi.org/10.4062/biomolther.2012.20.3.256 |